IONTAS today announced it has entered into a collaboration agreement with Inotrem, a specialist in immunotherapy for acute and chronic inflammatory syndromes. As part of the agreement, IONTAS will apply its Mammalian Display technology to identify antibodies involved in the TREM-1 pathway.

Leading global antibody discovery companies FairJourney Biologics and IONTAS announce partnership in search for SARS-CoV-2 treatment

John McCafferty, founder and CEO at IONTAS has recently been appointed Affiliated Professor at the Technical University of Denmark (DTU) Bioengineering.